-
Voluntary Announcement - Ascletis Announces Poster Presentations on the Study Results of Oral Small Molecule GLP-1R Agonist ASC30 and Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate ASC47 at the 85th Scientific Sessions of American Diabetes
2025-06-09
-
Voluntary Announcement - Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints
2025-06-04
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2025
2025-06-03
-
Inside Information - Final Judgment on Legal Proceedings Involving ASC41 and ASC43F
2025-05-30
-
Voluntary Announcement - Ascletis Announces U.S. FDA Clearance of IND Application for Its Oral Small Molecule IL-17 Inhibitor, ASC50, for the Treatment of Psoriasis
2025-05-22
-
Poll Results of Annual General Meeting Held on May 22, 2025
2025-05-22
-
Voluntary Announcement - Ascletis Announces First Participants Dosed in a U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity
2025-05-20
-
Voluntary Announcement - Ascletis Announces Oral and Poster Presentations on ASC47, an Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate for Obesity at the 32nd European Congress on Obesity
2025-05-06
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2025
2025-05-06
-
Next Day Disclosure Return - Others
2025-04-30
浙公网安备 33010802003344号
浙ICP备11050387号-1